|
|
|
Volumn 24, Issue 3 SUPPL. 8, 1997, Pages
|
|
A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GEMCITABINE;
IFOSFAMIDE;
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
RIBONUCLEOTIDE REDUCTASE;
ADULT;
AGED;
ANTINEOPLASTIC ACTIVITY;
CANCER GRADING;
CANCER STAGING;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE ASSOCIATION;
DOSE RESPONSE;
FEMALE;
HUMAN;
INFECTION RISK;
LUNG NON SMALL CELL CANCER;
MAJOR CLINICAL STUDY;
MALE;
NEUTROPENIA;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SOLID TUMOR;
SURVIVAL RATE;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
DRUG ANTAGONISM;
LUNG TUMOR;
MIDDLE AGED;
PHASE 2 CLINICAL TRIAL;
TREATMENT OUTCOME;
ADULT;
AGED;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS, ALKYLATING;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, NON-SMALL-CELL LUNG;
DEOXYCYTIDINE;
FEMALE;
HUMANS;
IFOSFAMIDE;
LUNG NEOPLASMS;
MALE;
MIDDLE AGED;
NEUTROPENIA;
RIBONUCLEOTIDE REDUCTASES;
TREATMENT OUTCOME;
|
|
EID: 0030981425
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (10)
|
|
References (10)
|
